Profile: LipoScience Inc (LPDX.OQ)
5.55USD
12:52pm EDT
$-0.88 (-13.69%)
$6.43
$6.30
$6.30
$5.42
19,651
22,572
$11.67
$5.42
LipoScience, Inc., incorporated on June 15, 2000, is a vitro diagnostic company. The Company’s diagnostic test, the nuclear magnetic resonance (NMR) LipoProfile test, directly measures the number of low density lipoprotein (LDL), particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. As of January 25, 2013, over eight million NMR LipoProfile tests were ordered. The Vantera system is its automated clinical analyzer. In August 2012, the Company received Food and Drug Administration (FDA) clearance to market the Vantera system commercially to laboratories.
The Company's technology platform combines signal processing algorithms and NMR spectroscopic detection into a clinical analyzer to identify and quantify concentrations of lipoproteins and, potentially, small molecule metabolites. The Company’s Vantera system is the Company's automated clinical analyzer. The Company's NMR LipoProfile test has been cleared by the FDA for use in the Company's clinical laboratory and directly measures LDL-P for use in managing cardiovascular risk.
Company Address
LipoScience Inc
2500 Sumner Boulevard
RALEIGH NC 27616-3235
P: +1919.2121999
F: +1302.6365454
Company Web Links
| Name | Compensation |
|---|---|
Buzz Benson |
-- |
Richard Brajer |
734,727 |
Lucy Martindale |
431,053 |
James Otvos |
242,537 |
Timothy Fischer |
1,019,040 |

